Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | METAP2 | P50579 | 1/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | KLK1 | P06870 | 4/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23343606 | 0.82 | POLB (0.42) | POLBNPSR1TSHRKLKB1KLK1 | |
| SCHEMBL21527211 | 0.81 | POLB (0.44) | POLBNPSR1TSHRKLKB1KLK1 | |
| SCHEMBL21201599 | 0.81 | POLB (0.41) | POLBNPSR1TSHRKEAP1NFE2L2 | |
| SCHEMBL924028 | 0.73 | TSHR (0.54) | POLBNPSR1TSHR | |
| SCHEMBL22148817 | 0.72 | MET (0.36) | TSHR | |
| SCHEMBL16891528 | 0.71 | MAPT (0.61) | POLBNPSR1KLKB1KEAP1NFE2L2 | |
| SCHEMBL14611520 | 0.71 | MAPT (0.57) | POLBNPSR1LMNATP53 | |
| SCHEMBL28003324 | 0.68 | POLB (0.55) | POLBNPSR1LMNASMN1; SMN2 | |
| SCHEMBL9752787 | 0.68 | POLB (0.63) | POLBNPSR1KLKB1KEAP1NFE2L2 | |
| SCHEMBL9752644 | 0.68 | POLB (0.58) | POLBNPSR1TSHRLMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2021-05-11 | — | — | US | disclosed |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | DRI UK LP (KY) | 2019-10-03 | — | — | US | disclosed |
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2019-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10364238-B2 | N-((het) arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | POLB 4140/4885NPSR1 372/4885TSHR 1196/4885 |
| US-20190300517-A1 | N-((HET)Arylmethyl)-Heteroaryl-Carboxamides Compounds As Plasma Kallikrein Inhibitors | KLKB1, BDKRB1, BDKRB2 | POLB 3901/4885NPSR1 442/4885TSHR 1220/4885 |
| US-11001578-B2 | N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as plasma kallikrein inhibitors | KLKB1, BDKRB1, BDKRB2 | POLB 3901/4885NPSR1 442/4885TSHR 1220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.